30.05.2016 • NewsElaine BurridgeBASFCoating Systems

BASF Sells Coating Systems Line to Colorcon

(c) BASF
(c) BASF

BASF is selling its Kollicoat IR Coating Systems product line to US-based Colorcon for an undisclosed sum. The sale, which is subject to approval by the Brazilian competition authorities, includes BASF’s current customer business, inventory and relevant knowhow.

Colorcon said the addition of Kollicoat complements its existing film coating portfolio and expands the options available to its customers. The company added that the acquisition would also further strengthen its existing activities with PVA-based pigmented, ready-to-use film coatings for use on immediate release forms of pharmaceuticals and dietary supplements.

Kelly Boyer, Colorcon’s general manager coatings, said the deal enabled both companies to focus on their core competences and further strengthened their existing cooperation which was announced in October 2014.

The companies said they look forward to expanding their cooperation by combining BASF’s polymer expertise with Colorcon’s formulation and application knowledge. BASF said it would focus on developing and promoting innovative film coating polymers including Kollicoat IR. The transfer of Kollicoat IR Coating Systems does not affect BASF’s Kollicoat IR polymer business.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.